Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Lymphoma × capivasertib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1 Lymphoid 1

Conditions

Breast Neoplasms 17 Prostatic Neoplasms 6 Triple Negative Breast Neoplasms 5 Neoplasm Metastasis 4 Recurrence 2 Ovarian Neoplasms 2 Neoplasms 2 Melanoma 2 Leukemia 2 Healthy Participants 2 Endometrial Neoplasms 2 Disease Progression 2 Uterine Cervical Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Solid Tumour 1 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1 Non-small Cell Lung Cancer Metastatic 1 Moderate Hepatic Impairment 1 Metastatic Castration-resistant Prostate Cancer (mCRPC) 1 Lymphoma, Mantle-Cell 1 Lymphoma, Follicular 1 Lymphoma, B-Cell, Marginal Zone 1 Lymphoma, B-Cell 1 Lymphoma 1 Lung Neoplasms 1 Hereditary Sensory and Autonomic Neuropathies 1 Hematologic Neoplasms 1 Healthy Volunteers (Intended Indication: Metastatic Patients With Triple Negative or HR+ Breast Cancer, or Hormone Sensitive Prostate Cancer) 1

Interventions

Cyclophosphamide 393 Rituximab 344 Etoposide 199 Vincristine 185 Filgrastim 178 Doxorubicin 175 Prednisone 149 Radiotherapy 140 Cytarabine 140 fludarabine phosphate 125 Methotrexate 118 Melphalan 114 Peripheral Blood Stem Cell Transplantation 110 fludarabine 104 Busulfan 86 Dexamethasone 81 Carmustine 65 Granulocyte Colony-Stimulating Factor 63 Tacrolimus 60 Gemcitabine 59 Mycophenolic Acid 57 Whole-Body Irradiation 56 Bendamustine Hydrochloride 56 Lenalidomide 55 Antilymphocyte Serum 55 Ifosfamide 53 Cyclosporine 52 Bortezomib 50 Methylprednisolone 43 Leucovorin 42

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07294677 2026-03-04

CAVALRY

University of Chicago

Phase 1/2 Recruiting

LymphoidOther hematologic neoplasm

Leukemia, Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡